EuroBiotech—More Articles of Note

Newspapers

> Lytix Biopharma rejigged its board of directors ahead of a planned IPO. The changes leave the cancer biotech with a more equal gender split, a requirement for publicly listed companies in its native Norway. Release

> Roche moved its AC Immune-partnered Alzheimer’s candidate into phase 2. The companies are developing the anti-Tau antibody, RG6100, for use in patients with prodromal to mild Alzheimer's disease. Presentation (PDF)

> Antabio raised €7.3 million ($8.7 million). The series A round equips the French biotech to take its inhibitor of bacterial metallo beta-lactamases up to the end of phase 1. Statement

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Ablynx set the terms on its $150 million IPO and accompanying $25 million private placement. The listing gives the Belgian biotech a $1.5 billion market cap. Release 

> Silence Therapeutics stepped up its legal action against Alnylam and The Medicines Company. Statement

> Redx revealed it is edging closer to the end of its bankruptcy ordeal. A court is due to hear its application to be rescued as a going concern next week. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.